For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.
Delivering the Added Dimension in Drug Discovery Services
Drug Metabolism and Pharmacokinetics (DMPK) is an
integral part of drug
discovery. Its central role is to contribute to the optimization of
novel chemical entities in drug discovery by balancing the properties associated with
drug gastrointestinal absorption (for orally delivered therapies),
distribution, clearance, elimination and DDI potential as rapidly and
cost-effectively as possible.
The DMPK department comprises in-vitro, in-vivo, metabolite ID and pre-formulation groups, managed by highly experienced and matured scientists. We guide discovery projects by troubleshooting scientific issues and offer changes on scaffolds to drive discovery projects in the right direction and de-risk failures in the later stage of development due to DMPK related issues.
Jubilant’s DMPK technical and research services meet the highest standards of professional performance to satisfy the unique requirements of our clients. Our team supports both integrated pre-clinical discovery programs and fixed-fees-for-services (FFS) projects and delivers quality and reproducible results with quick turnaround time. We work closely with our clients to identify their needs and clarify their expectations, including cost and time constraints.
In-vitro ADME Services
The team provides in-vitro ADME services (absorption, distribution, metabolism and excretion) with the expertise to guide discovery projects from hit identification, through hit to lead optimization, and then lead optimization up to the identification of clinical candidates. To reduce the chance of failures in development, we troubleshoot and offer changes on scaffolds for a quick go/no-go decision at the discovery stage.
In-vitro ADME Screening
The team has a track record to carry various in-vitro studies or in-vitro ADME screening at various stages of the drug discovery and development process to flag potential issues such as:
Physiochemical studies – Kinetic solubility, thermodynamic solubility in PBS, SGF, SIF, chemical stability, early formulation assessment, etc.
In-vitro metabolism services – Metabolic stability using liver microsomes/hepatocytes/rCYPs/S-9 fraction, CYP inhibition, CYP phenotyping and CYP induction (using PXR cell lines), CYP profiling to understand the involvement of CYP enzymes, blood/plasma/brain/tissue/microsomal protein binding, stability in plasma, buffer, blood, blood/plasma ratio, GSH adduct, TDI, etc.
In-vitro permeability and transporter studies – PAMPA, MDR 1-MDCK/Caco-2 permeability, inhibition and substrate assessment of P-gp and BCRP transporters.
PK studies by various routes (oral, intraperitoneal, intravenous, subcutaneous, etc) in mice, rats, rabbits, hamsters, guinea pigs and dogs (dogs in-life phase will be outsourced to a third party), dose range finding studies, brain exposure study, etc.
Biliary and urine excretion study
The DMPK team has published several research articles in peer-reviewed international journals and presented posters in conferences.
Solubility (thermodynamic and kinetic method)
Biorelevant medium (FaSSIF, FaSSGF, FeSSIF)
MDCK (wild type)
Pharmacokinetics by various routes, viz. oral, intravenous, intraperitoneal, subcutaneous in mice (Swiss Albino, C57/BL, Balb/C), rats (Wistar, Sprague Dawley), rabbits (New Zealand White), Guinea pigs (Golden Syrian) dogs (Beagle), etc.
Ocular PK studies in rats and rabbits
Brain to plasma ratio
Biliary and urine excretion
Plasma protein binding (ultra-filtration and equilibrium dialysis)
Microsomal protein binding
Cytochrome P450 inhibition
Cytochrome P450 time dependent inhibition
Identification of in-vitro (microsomes, S9 and hepatocytes) and in-vivo samples (plasma, bile, urine, etc.)
Can we have some information?
Please fill out our short form in order to activate your download.
Thank you. Please click the button to start your download.